Tumor penetration of AMSA in man

Guo Zhengang, Niramol Savaraj, Lynn G Feun, Katherine Lu, David J. Stewart, Mario Luna, Robert S. Benjamin, Ti Li Loo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

4)9-Acridinylamino)-methanesulfon-m-anisidide [AMSA) has shown significant antitumor activity against several murine tumors and leukemias. During its Phase I and II clinical trial, we were able to obtain tumors, plasma, and CSF specimens from patients who received varying doses of AMSA, as well as patients who received high doses and had autologous bone marrow rescue. The drug was analyzed chromatographically. The tumor to plasma drug concentration ratios ranged from 200% to 486% apparently independent of dose and sampling time. Because AMSA was not detected in the CSF, the drug may not be effective in the treatment of meningeal metastasis. High-dose AMSA therapy with bone marrow rescue did not result in significantly higher AMSA concentrations in the tumor, nor did it elicit favorable response.

Original languageEnglish
Pages (from-to)475-478
Number of pages4
JournalCancer Investigation
Volume1
Issue number6
DOIs
StatePublished - Jan 1 1983
Externally publishedYes

Fingerprint

Neoplasms
Bone Marrow
Pharmaceutical Preparations
Phase II Clinical Trials
Clinical Trials, Phase I
Leukemia
Neoplasm Metastasis
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zhengang, G., Savaraj, N., Feun, L. G., Lu, K., Stewart, D. J., Luna, M., ... Loo, T. L. (1983). Tumor penetration of AMSA in man. Cancer Investigation, 1(6), 475-478. https://doi.org/10.3109/07357908309020272

Tumor penetration of AMSA in man. / Zhengang, Guo; Savaraj, Niramol; Feun, Lynn G; Lu, Katherine; Stewart, David J.; Luna, Mario; Benjamin, Robert S.; Loo, Ti Li.

In: Cancer Investigation, Vol. 1, No. 6, 01.01.1983, p. 475-478.

Research output: Contribution to journalArticle

Zhengang, G, Savaraj, N, Feun, LG, Lu, K, Stewart, DJ, Luna, M, Benjamin, RS & Loo, TL 1983, 'Tumor penetration of AMSA in man', Cancer Investigation, vol. 1, no. 6, pp. 475-478. https://doi.org/10.3109/07357908309020272
Zhengang, Guo ; Savaraj, Niramol ; Feun, Lynn G ; Lu, Katherine ; Stewart, David J. ; Luna, Mario ; Benjamin, Robert S. ; Loo, Ti Li. / Tumor penetration of AMSA in man. In: Cancer Investigation. 1983 ; Vol. 1, No. 6. pp. 475-478.
@article{d52bcc81f1374eec992f7b4974105854,
title = "Tumor penetration of AMSA in man",
abstract = "4)9-Acridinylamino)-methanesulfon-m-anisidide [AMSA) has shown significant antitumor activity against several murine tumors and leukemias. During its Phase I and II clinical trial, we were able to obtain tumors, plasma, and CSF specimens from patients who received varying doses of AMSA, as well as patients who received high doses and had autologous bone marrow rescue. The drug was analyzed chromatographically. The tumor to plasma drug concentration ratios ranged from 200{\%} to 486{\%} apparently independent of dose and sampling time. Because AMSA was not detected in the CSF, the drug may not be effective in the treatment of meningeal metastasis. High-dose AMSA therapy with bone marrow rescue did not result in significantly higher AMSA concentrations in the tumor, nor did it elicit favorable response.",
author = "Guo Zhengang and Niramol Savaraj and Feun, {Lynn G} and Katherine Lu and Stewart, {David J.} and Mario Luna and Benjamin, {Robert S.} and Loo, {Ti Li}",
year = "1983",
month = "1",
day = "1",
doi = "10.3109/07357908309020272",
language = "English",
volume = "1",
pages = "475--478",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Tumor penetration of AMSA in man

AU - Zhengang, Guo

AU - Savaraj, Niramol

AU - Feun, Lynn G

AU - Lu, Katherine

AU - Stewart, David J.

AU - Luna, Mario

AU - Benjamin, Robert S.

AU - Loo, Ti Li

PY - 1983/1/1

Y1 - 1983/1/1

N2 - 4)9-Acridinylamino)-methanesulfon-m-anisidide [AMSA) has shown significant antitumor activity against several murine tumors and leukemias. During its Phase I and II clinical trial, we were able to obtain tumors, plasma, and CSF specimens from patients who received varying doses of AMSA, as well as patients who received high doses and had autologous bone marrow rescue. The drug was analyzed chromatographically. The tumor to plasma drug concentration ratios ranged from 200% to 486% apparently independent of dose and sampling time. Because AMSA was not detected in the CSF, the drug may not be effective in the treatment of meningeal metastasis. High-dose AMSA therapy with bone marrow rescue did not result in significantly higher AMSA concentrations in the tumor, nor did it elicit favorable response.

AB - 4)9-Acridinylamino)-methanesulfon-m-anisidide [AMSA) has shown significant antitumor activity against several murine tumors and leukemias. During its Phase I and II clinical trial, we were able to obtain tumors, plasma, and CSF specimens from patients who received varying doses of AMSA, as well as patients who received high doses and had autologous bone marrow rescue. The drug was analyzed chromatographically. The tumor to plasma drug concentration ratios ranged from 200% to 486% apparently independent of dose and sampling time. Because AMSA was not detected in the CSF, the drug may not be effective in the treatment of meningeal metastasis. High-dose AMSA therapy with bone marrow rescue did not result in significantly higher AMSA concentrations in the tumor, nor did it elicit favorable response.

UR - http://www.scopus.com/inward/record.url?scp=0021044890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021044890&partnerID=8YFLogxK

U2 - 10.3109/07357908309020272

DO - 10.3109/07357908309020272

M3 - Article

C2 - 6689404

AN - SCOPUS:0021044890

VL - 1

SP - 475

EP - 478

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 6

ER -